Biological Dynamics, Perlmutter Cancer Center at NYU Langone Health collaborate on pancreatic cancer rese

Study to investigate effectiveness of early-stage pancreatic cancer detection using patented exosome-isolation technology

Biological Dynamics, a company commercializing its exosome-isolation ExoVerita platform, announced a collaboration with the Perlmutter Cancer Center at NYU Langone Health to validate its application for the early detection of pancreatic ductal adenocarcinoma (PDAC).

The collaboration will test retrospective samples from over 200 patients starting this month. The ExoVerita platform is being investigated at NYU Langone Health, among other premier institutions, with a goal of advancing treatment options for high-risk PDAC patients.

"Pancreatic cancer is predicted to be the second leading cause of cancer-related deaths by 2030. Exploring new technologies that can detect cancers sooner in high-risk patients is critical to improving patient outcomes and the quality-of-life years following diagnosis," says principal investigator, Diane Simeone, MD, surgical oncologist and director, pancreatic cancer center at NYU Langone's Perlmutter Cancer Center. "I am very interested in collaborating with Biological Dynamics to advance research in developing an early detection blood-based test for pancreatic cancer."